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Abstract
Background: The presence of chicken group-IIA PLA2 (ChPLA2-IIA) in the intestinal secretion suggests that this
enzyme plays an important role in systemic bactericidal defence. We have analyzed the bactericidal activity of
purified ChPLA2-IIA, on several gram-positive and gram-negative bacteria by using the diffusion well and dilution
methods.
Results: ChPLA2-IIA displays potent bactericidal activity against gram-positive bacteria but lacks bactericidal activity
against gram negative ones. We have also demonstrated a synergic action of ChPLA2-IIA with lysozyme when
added to the bacteria culture prior to ChPLA2-IIA. The bactericidal efficiency of ChPLA2-IIA was shown to be
dependent upon the presence of calcium ions and then a correlation could be made to its hydrolytic activity of
membrane phospholipids. Interestingly ChPLA2-IIA displays a higher dependence to Ca2+ ions than to Mg2+ions.
Conclusion: We conclude that the main physiological role of ChPLA2-IIA could be the defence of the intestine
against bacterial invasions.
Background
Phospholipase A2 (PLA2) comprises a diverse family of
enzymes that catalyzes the hydrolysis of glyceropho-
spholipids at the sn-2 position to produce free fatty
acids and lysophospholipids [1,2]. At present, mamma-
lian secreted PLA2s (sPLA2) are classified into groups I,
II, V, and X. Group II sPLA2 has been further classified
into five subtypes (Type IIA, IIC, IID, IIE, and IIF) on
the basis of their primary sequences. Group IIA PLA2 is
one of the key enzymes in the process of inflammation
that regulates the synthesis of arachidonic acid and lyso-
phospholipids [3-5]. The structure of human group IIA
PLA2 is unusual because of the highly cationic nature of
the protein with a great number of positively charged
residues (arginine and lysine) spread all over its surface
[6]. This provides a molecular explanation for its well
established physiological antibacterial activity. Further-
more, tissue and cellular localisations of the enzyme are
consistent with its antibacterial role. Indeed, high con-
centrations of group IIA PLA2 are expressed in Paneth
cells of the small intestine [7-11], as well as in human
lacrimal cells (and found in tears) [12,13] and in human
prostate cells (and found in seminal plasma) [14]. These
various localisations are related to possible sites of bac-
terial invasion into externally-exposed body cavities. The
bactericidal potency of rabbit [15], mouse [8], and
human [16] group IIA PLA2 is mostly directed against
Gram-positive bacteria. However, Harwig and coworkers
showed that murine intestinal group IIA PLA2 is bacter-
icidal against some Gram-negative bacteria, such as
Escherichia coli, Salmonella, and pseudomonas [8].
Enzymatic activity (phospholipolysis) is required for
the bactericidal activity of mammalian group IIA sPLA2
[8,15,17]. It has been suggested that bacterial envelope
sites engaged in cell growth may represent preferential
sites for the action of group IIA sPLA2 against Gram-
positive bacteria [18].
Overall, bacterial cell wall components, outside of the
membrane phospholipids, seem to provide a physical
barrier for the access of sPLA2 to their substrates.
Furthermore, the cell wall of gram positive bacteria
b e a r sah i g h l ya n i o n i cc h a r g ed u et ot h ep r e s e n c eo f
phosphate diester units of lipotechoic acid. The struc-
ture of the gram negative bacteria cell wall is much
more complex since it contains 10% to 20% of lipids
with a thin layer of peptidoglycan surrounded by
an external membrane of phospholipids containing
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any medium, provided the original work is properly cited.lipopolysaccharides (LPS) and proteins. The bactericidal
action of group IIA sPLA2 against Gram-negative
bacteria is more difficult to explain than its action against
Gram-positive bacteria. In the later case, the sPLA2 pass
through the highly anionic cell wall of gram positive bac-
teria to reach their target phospholipids. The number
and the location of positive charges on the surface of the
enzyme could be important for the bactericidal activity of
sPLA2. The purpose of the present study was to evaluate
the possible mechanisms of chicken group IIA PLA2
when killing various antibiotic- resistant or sensitive bac-
terial strains. For this purpose we used native group IIA
PLA2, previously purified from chicken mucosa and we
measured its bactericidal properties. Comparative studies
were performed using the PLA2 group IB purified from
chicken pancreas. We showed that ChPLA2-IIA was
more effective than ChPLA2-IB in killing the Gram-posi-
tive bacterial. The role of lysozyme as a defensive enzyme
has been well documented in vertebrates [19,20] and
insects [21-25]. In order to establish if there is a synergis-
tic action between group IIA PLA2 and lysozyme, we
tested the antibacterial effect of ChPLA2-IIA against bac-
teria after pre-incubation with 2 mg/ml (final concentra-
tion) of lysozyme.”
Results
Antibacterial activity of ChPLA2-IIA
We performed the well diffusion methods .to test the anti-
bacterial activity of 13 μg of Ch PLA2-IIA added to 10
8
cells of growing culture of gram-positive bacteria: Bacillus
cereus (BC), micrococcus luteus (ML), Brevibacterium
flavum(BF), Staphylococcus aureus (SA), Staphylococcus
epidermis(SEp), Bacillus subtilis (BS), Enterococcus faecalis
(EF),a n denterococcus faecium (EFa), and gram negative
bacteria: Pseudomonas Aeruginosa,( Ps), Salmonella (S),
and Klebsielle pneumoniae (KP), Enterobacter cloacae (EC)
and E. coli (ECo). Bacteria were incubated for 24 hours.
ChPLA2-IIA was active against closely related Bacillus
species, but also some other Gram-positive bacteria (Table
1). Indeed, the enzyme exhibited an important bactericidal
effect against BC, BS and ML with a diameter of inhibition
higher than 20 mm. A moderate bactericidal effect was
obtained with a diameter of inhibition between 15 and 20
mm against EF and BF. This antibacterial PLA2 activity
was much less with an inhibition diameter lower than 15
mm against EF, SA and SEp. Whereas, ChPLA2-IIA
shows no antibacterial activity against Gram-negative bac-
teria (EC, Ps, S, KP and EC o ).
The bactericidal effects of ChPLA2-IIA were also
tested by measuring the number of CFU after incubat-
ing live bacteria with various concentrations of sPLA2
for various times (see material and methods). As we
can see in Figure 1, the decrease of cell viability began
slow at the first 10 minutes of incubation. Very
effective Gram-positive bactericidal activity was
observed for ChPLA2-IIA, even at the lowest concen-
tration tested of 15 μg/ml. The enzyme killed 75% of
BS and ML, 60% of BC and 50% of SEp after 15 min
of incubation. However, 30 μg/ml of ChPLA2-IIA dis-
played bactericidal activity and killed 90% of ML and
80% of BS and BC after 2 h of incubation. At a final
concentration of 45 μg/ml, ChPLA2-IIA killed 85% BS,
ML, BF, BC and SEp, and 50% of EF in 2 hours. How-
ever, no bactericidal activity was measured against Ps,
S ,K P ,EC o ,M La n dE C ,e v e na tt h eh i g h e s tc o n c e n -
tration tested (Figure 2).
Pancreatic ChPLA2-IB displayed poor bactericidal
activity only against BF and ML at the highest final con-
centration tested of 100 μg/ml. In fact, 100 μg/ml (final
concentration) ChPLA2-IB killed only 20% of these tow
above mentioned bacteria after 1 hour, but was inactive
against the other bacteria strains tested.
Effects of divalent cations
We have tested the effect of Ca2+ ion on the antibacter-
ial activity of ChPLA2-IIA against ML and BS as
described in materiel and methods.
Figure 3 shows that the addition of 0.7 mM CaCl2 to
t h ee n z y m ei n c u b a t e dw i t h1 0
7 bacteria enhanced the
bactericidal potency of ChPLA2-IIA between 35% to
79% compared to the bactericidal activity without addi-
tion of Ca2+. Whereas addition of 2 mM EGTA, abol-
ished its antimicrobial activity even when the incubation
mixture contained 0.7 mM calcium.
Table 1 Inhibitory spectrum of ChPLA2-IIA on several
Gram-positive and gram-negative bacteria
Bacteria stain Gram Sensitivity IC50 (μg/ml)
Bacillus cereus + +++ 12
Bacillus subtilis + +++ 9.5
Micrococcus luteus + +++ 9
Brevibacterium flavum ++ + 1 4
Enterococcus faecium ++ + -
Enterococcus faecalis ++ 3 4
Staphylococcus aureus ++ 1 9
Staphilococcus epidermidis ++ 1 4
Enterobacter cloacae -- -
Klebsielle pneumoniae -- -
Escherchia coli -- -
Salmonella -- -
Pseudomonas aeruginosa -- -
The bactericidal level was estimated by measuring the size of inhibition zone
of the indicator strain. Inhibitory concentration reducing 50% the bacterial
growth of gram(+) bacteria.
Insensitivity (-), low sensitivity (+: Diameter of inhibition < 15 mm), high
sensitivity (++: Diameter of inhibition between 15 et 20 mm) and very high
sensitivity (+++: Diameter of inhibition > 20 mm).
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Figure 1 In vitro bactericidal activity of chicken sPLA2-IIA. Samples of gram positive bacterial suspensions were taken after incubation with
chPLA2-IIA at various concentrations for 20, 60 and 120 min and thereafter cultured on agar. Bacterial viability was assessed by measuring
colony forming ability as described in “Materials and Methods”. The results shown in the figure are means of two independent tests. The sPLA2
final concentrations were follows: white circle = 15 μg/ml sPLA2-IIA, white triangle = 30 μg/ml sPLA2-IIA, white square = 45 μg/ml sPLA2-IIA,
black square = 50 μg/ml sPLA2-IB.
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Page 3 of 10“The low activity of ChPLA2-IIA, without purposely
added calcium (Figure3, solid circles), is probably due to
the presence of calcium in the BHI medium. Interest-
ingly, the presence of 0.7 mM Mg2+ increases the bac-
tericidal effect of ChPLA2-IIA but to a lower extent as
compared to that of Ca2+ ions. However both Ca2+
ions and Mg2+ ions added to the incubation mixture,
g a v et h es a m eC h P L A 2 - I I Aa c t i v i t yc o m p a r e dt ot h e
pre-incubation mixture with the Ca2+ ions only. This
observation suggests that ChPLA2-IIA possesses a
higher affinity to Ca2+ ions than that to Mg2+ ions.
Similar results were obtained with human and murine
group IIA sPLA2 [12]. Thus antibacterial activity of
ChPLA2-IIA seems to be related to its enzymatic
activity.
Synergy between ChPLA2-IIA and lysozyme activities
Lysozyme hydrolyse the b-1,4 glucosidic linkage between
N-acetyl muramic acid and N-acetyl glucosamine of
peptidoglycan, a cell wall component of bacteria. We
first measured lysozyme bactericidal activity against the
full set of gram+ and gram- bacteria. A highly variable
ability of lysozyme to hydrolyse suspension of bacteria
was observed (Figure 4). The highest Lysozyme activity
was much higher against gram positive bacteria espe-
cially against suspension of ML and BS. A fast decrease
of cells viability was observed during the first minutes.
To evaluate possible synergic effects between lysozyme
and ChPLA2-IIA bactericidal activities, we have chosen
ML and BS for their high sensitivity to lysozyme. After
two minutes of pre-treatment with lysozyme, the
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Figure 2 In vitro bactericidal activity of chicken sPLA2-IIA. Samples of gram negative bacterial suspensions were taken after incubation with
sPLA2 at various concentrations for 20, 60 and 120 min and thereafter cultured on agar. Bacterial viability was assessed by measuring colony
forming ability as described in “experimental procedures”. The results shown in the figure are means of two independent tests. The sPLA2 final
concentrations were follows: white circle = 15 μg/ml sPLA2-IIA, white triangle = 30 μg/ml sPLA2-IIA, white square = 45 μg/ml sPLA2-IIA, black
square = 50 μg/ml sPLA2-IB.
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Figure 3 Calcium dependency of the antibacterial activity. ChPLA2-IIA was tested against ML and BS bacteria. Strains were incubated with
0.5 and 10 μg/ml (final concentrations) of sPLA2-IIA without or with 0.7 mM divalent cations as indicated. Each symbol represents a mean value
from three separate experiments. Results are given as mean values of duplicate determination of CFU.
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increases the ability of the PLA2 to kill the bacteria
(Figure 5). The IC50 values of ChPLA2-IIA decrease
from 9 μg/ml to 4.5 μg/ml against ML and from
9.5 μg/ml to 6 μg/ml against BS. The inhibition ratio of
ML increases from 85% to reach 91% after 2 h. This
ratio is defined as the rate of the live bacteria number
without addition of the PLA2 devised by the live bac-
teria number counted after the PLA2 addition.
Discussion
Bactericidal activity of chicken sPLA2
Chicken intestinal sPLA2 is an 18 kDa molecule com-
posed of 134 amino acid residues. It has been purified
from the intestine mucosa (Karray A, Frikha F, Ben Ali
Y, Gargouri Y, Bezzine S: Purification and Biochemical
Characterization of Cationic Chicken Intestinal phos-
pholipase A2, submitted). In this previous work, we
demonstrated that ChPLA2-IIA hydrolyzes phosphati-
dylglycerol (which is the main phospholipid present in
microbial membranes) more rapidly than phosphatidyl-
choline (abundant in mammalian cell membranes)[26].
In the present work, we have demonstrated that only 15
μg/ml (final concentration) of ChPLA2-IIA is able to kill
75% of BS and ML, and IC50 values are 9 μg/ml and 9.5
μg/ml, respectively. The same amount of enzyme kills
60% of BC with an IC50 value of 12 μg/ml. ChPLA2-IIA
was less active against BF, SA, SEp and EF with IC50
values of 12,14,19 and 34 μg/ml, respectively. Whereas,
even at a final concentration of 50 μg/ml, ChPLA2-IIA
is inactive against gram negative bacteria.
The cell wall of gram positive bacteria contains a dense
peptidoglycan array, which bears a high anionic charge
due to the presence of phosphate diester units of lipotei-
choic acid. The sPLA2 must go through the highly anio-
nic cell wall of Gram positive bacteria to reach the
phospholipids membrane target. ChPLA2-IIA, with an
electrostatic potential of +16 (+23; -7) based on the total
number of Lys, Arg, His, Asp and Glu, can bind highly
anionic bacterial cell walls [27], in contrast to the PLA2
group IB with a net tabulated charge of +1 (+19, -18).
A previous study showed the ability of human sPLA2-
IIA to kill Bacillus antracis, the etiological agent of
antrax [28]. The authors showed that both germinated
B. anthracis spores and encapsulated bacilli were sensi-
tive to the bactericidal activity of human sPLA2-IIA in
vitro. Moreover, the human PLA2-IIA appears to be a
major antibacterial factor against Gram positive bacteria
in human acute phase serum. The bactericidal activity
of human PLA2-IIA was also shown against Staphylo-
coccus aureus and Listeria monocytogenes in serum sam-
ples collected from patients with acute bacterial
infections and healthy control subjects [29].
Pancreatic ChPLA2-IB, also tested, at a high final con-
centration of 50 μg/ml didn’t show any bactericidal
activity, similar to the porcine, human, and mouse pan-
creatic sPLA2 [27,30]. Infact, 0.5 μg/ml (final concentra-
tion) of human PLA2-IIA killed over 90% of gram
positive bacteria, but was inactive against E.coli even at
higher concentration. However, human and mouse
group-IB PLA2 displayed modest bactericidal activity
against Listeria monocytogene [30].
L
y
s
o
s
o
m
a
l
 
A
c
t
i
v
i
t
y
 
(
U
/
m
l
)
BC BS    ML    BF     EF    EFa   SEp SA   ECo   KP     S     Ps    EC
0.08
0.06
0.04
0.02
0
Figure 4 Initial rates of hydrolysis of lysozyme against several lyophilized bacteria. Substrate suspensions (10
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with 2.5 mg/ml of lysozyme. One enzyme unit was defined as the amount causing decrease of 0.1 absorbance units at 540 nm in the reaction
for 1 min at 25°C. The essay was performed in triplicate per sample.
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activity of mammalian group IIA sPLA2 against Gram-
positive [8,13] and Gram-negative [18] bacteria. It has
been suggested that bacterial envelope sites engaged in
cell growth may represent preferential sites for the
action of group IIA sPLA2 against Gram-positive bac-
teria [15]. Moreover, bacteria are more resistant to
group IIA sPLA2 in the stationary phase than in the
logarithmic growth phase, suggesting that these micro-
organisms are more susceptible to sPLA2 when they
are dividing [15]. Overall, bacterial cell wall compo-
nents outside of the phospholipid membrane seem to
provide a barrier for the access of sPLA2 to the phos-
pholipid membrane surface. However, the bactericidal
action of sPLA2 group IIA against Gram negative bac-
teria is more complex than its action against Gram-
positive ones.
Calcium dependency of ChPLA2 activity
We showed that bactericidal activity of ChPLA2-IIA is
calcium dependant since it was totally inhibited by
EGTA. This result suggests that the enzymatic activity
of ChPLA2-IIA was critical for its bactericidal proper-
ties. Qu and Lehrer [12] showed in previous work that
2 mM EGTA abolished the bactericidal effect of human
tears and greatly reduced their bactericidal activity
against Streptococci and Listeria monocytogene.T h i s
confirms that the antibacterial activity of PLA2 group
IIA from different species is linked to their enzymatic
hydrolysis of membrane phospholipids. Interestingly,
ChPLA2-IIA shows a much higher affinity to Ca2+ ions
as compared to Mg2+ ions since we found the same
bactericidal activity with Ca2+ ions alone or with Ca2+
and Mg2+ ions together.”
Synergic effect of ChPLA2-IIA with lysozyme
Our data provide compelling evidence that ChPLA2-IIA
is mostly responsible for killing a broad spectrum of
gram-positive bacteria not withstanding the presence of
lysozyme at higher concentrations. This inference is
supported by several lines of evidence. Firstly, much
lower concentrations of purified ChPLA2-IIA (15 μg/ml
final concentration) than those of lysozyme (2.5 mg/ml
final concentration) showed potent bactericidal activity
against the gram positive bacteria tested. Secondly, lyso-
zyme acts in synergy with the ChPLA2-IIA since a prior
treatment of the bacteria with 2 mg/ml (final concentra-
tion) of lysozyme increases the ability of the ChPLA2-
IIA to hydrolyse suspensions of intact ML. Thus, the
treatment of ML with lysozyme probably disrupts the
cell wall to allow a better access of the ChPLA2-IIA
to the cell membrane in order to hydrolyse the
phospholipids.
Sequence analysis of ChPLA2-IIA
In the present work the IC50 of ChPLA2-IIA was ran-
ging between 9 μg/ml (final concentration) and
35 μg/ml (final concentration). However, IC50 of human
and mouse PLA2-IIA were ranging between 1 ng/ml to
0.5 μg/ml [12,30]. These data indicate that ChPLA2-IIA
is less potent at killing Gram positive bacteria than
human PLA2-IIA. In a previous work, Koduri et al [30]
showed that the triple site mutations R7E/K10E/K16E
and K74E/K87E/R92E of basic residues on the putative
membrane binding surface of human PLA2-IIA
decreased greatly the antibacterial activity of the
enzyme. These basic residues reinforce the binding of
the human PLA2-IIA to the highly anionic phosphatidyl
glycerol which is abundant in bacterial membranes.
Aminoacid sequence alignment of human and chicken
PLA2-IIA shows that R7 and R92 are replaced by I and
Q, respectively which may explain the lower potency of
chicken PLA2-IIA at killing gram positive bacteria.
Interestingly, Staphylococcus aureus responds to PLA2
attack by continued phospholipid synthesis, and thus
the fate of the bacterium exposed to PLA2 depends on
the relative rates of phospholipid degradation and synth-
esis [31].
Conclusion
ChPLA2-IIA purified from the intestine mucosa pos-
sesses an antibacterial activity against all gram + bac-
teria tested and especially against ML, BS and BC but it
w a sm u c hl e s sa c t i v ea g a i n s tg r a m-b a c t e r i a .O nt h e
one hand, the antibacterial property of ChPLA2-IIA is
probably closely related to its enzymatic activity since
C a C l 2a n dM g C l 2( 0 . 7m M )a r er e q u i r e da n dt h e s e
activities are not observed in the presence of an ion che-
lator (2 mM EGTA). Moreover, ChPLA2-IIA possesses a
much higher affinity to Ca2+ ions than to Mg2+ ions.
Furthermore, ChPLA2-IIA acts in synergy with lyso-
zyme. A prior treatment of bacteria with 2 mg/ml (final
concentration) lysozyme disrupts the cell wall to allow a
better access of the ChPLA2-IIA to the cell membrane.
Materials and methods
Materials
Bovine serum albumine (BSA), sodium taurodeoxycho-
late (NaTDC), were from Sigma Chemical (St. Louis,
USA). Ethylene Diamine Tetra Acetic acid (EDTA) was
from Sigma-Aldrich (St. Quentin-Fallavier, France). Brain
Heart Infusion (BHI) was from Hispanlab, S.A (Madrid).
Enzyme samples
ChPLA2-IIA was purified from chicken intestine mucosa
( K a r r a yA ,F r i k h aF ,B e nA l iY ,G a r g o u r iY ,B e z z i n eS :
Purification and Biochemical Characterization of
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mitted). The specific enzymatic activity of ChPLA2-IIA
using a pH state assay is about 160 U/mg measured at
optimal conditions (pH 9.0 and 40°C) in the presence of
10 mM NaTDC and 10 mM CaCl2 using egg phosphati-
dylcholine as substrate. The chicken pancreatic sPLA2,
taken as a negative control was also purified in the
laboratory [32]. Lysozyme from chicken egg white was
purchased from sigma (France).
Bactericidal Assays
Diffusion well method
The antibacterial activity of ChPLA2-IIA was checked
by well diffusion method [33,34]. Briefly, bacteria were
cultivated in BHI medium at 37°C for 3 h. A basal layer
of BHI containing 2-5% agar, was poured in Petri
dishes. When plates were dried, 5 ml of soft BHI (0-7%
agar) containing 10
7 cells of the indicator strain were
overlaid.
Then, wells were punched in the agar plate and filled
with 5 μg of test samples. After 18 h of incubation at
37°C, the diameter of the zone of inhibition was mea-
sured. One arbitrary unit (AU) of antibacterial activity
was defined as the amount of ChPLA2-IIA sufficient to
give a zone of inhibition around the well.
The bacteria used were staphylococcus. aureus (SA),
staphylococcus epidermidis (SEp), Bacillus cereus (BC),
Bacillus subtilis (BS), Micrococcus Luteus (ML), Entero-
coccus faecalis (EF), Enterococcus faecium (EFa), Entero-
bacter cloacae (EC), Brevibacterium flavum (BF),
Pseudomonas Aeruginosa,( Ps), Salmonella (S), Klebsielle
pneumoniae (KP) and E. coli (ECo) (Table 1).
Dilution method
Bacterial viability was assessed by measuring colony-
forming ability of bacteria incubated in the absence or
presence of PLA2 for various times. Bacteria were first
incubated in 100 ml of BHI medium at 37°C for 3 h30
min. Thereafter, they were centrifuged at 200 rpm for
10 min at 4°C in an Eppendorf tube. Cell pellets were
suspended in 10 ml of sterile saline buffer and centri-
fuged as previously. This step was repeated twice. Then,
cells were suspended in saline buffer, and the OD650 nm
was adjusted to 0.5 (10
8 bacteria/ml). OD650 was mea-
sured with an Ultrospec III spectrophotometer (Pharma-
cia, Piscataway, NJ). Tow microliter of the suspension
was added to 500 μl of Tris buffer (50 mmol/L Tris, and
10 mmol/L Ca2+, 10 mg/ml bovine serum albumin, pH
7.4) and shaken. 20 μl of the bacterial suspension bac-
teria in tris buffer (20 mmol/liter Tris, 10 mmol/liter
Ca2+, 10 mg/ml bovine serum albumin, pH 7.4) was
added to 20 μl of sPLA2 solution. A mixture of 20 μlo f
bacterial suspension and 20 μl of sterile saline served as
a sPLA2 negative control. The resulting solutions thus
contained 45, 30, 15, and 0 μg/ml sPLA2. The sPLA2
negative control for ChPLA2 contained the same
amount of buffer as the 45 μg/ml sPLA2 solutions. The
solutions were incubated with bacteria at 37°C. Samples
were taken at 20, 60, and 120 min and plated on brain
heart infusion agar and grown for 18 h to measure col-
ony-forming units (CFU). The bactericidal tests were
performed twice on each bacterium and enzyme, and
the results are given as mean values of duplicate
determinations.
Effects of divalent cations on the ChPLA2-IIA antibacterial
activity
To determine the degree of which ChPLA2-IIA was cal-
cium and/or magnesium dependent, we evaluated the
effect of addition of 0.7 mM CaCl2, or MgCl2 on the
bactericidal activity. The addition of 2 mM EGTA, a
selective divalent cations chelator was also performed.
Incubation mixtures contained 2 10
7 bacteria/ml were
washed twice with sterile salt solution and supplemen-
t e dw i t h0 . 7m MC a C l 2 ,a n d( o r )0 . 7m MM g C l 2 ,
10 mg/ml sterile bovine serum albumin, and the appro-
priate amount of ChPLA2-IIA. Reactions were carried
out at 37°C for up to 2 h. At various time points, ali-
quots were taken and serially diluted into sterile saline
buffer and plated in agar dishes to determine CFU. An
aliquot was supplemented with 2 mM EGTA.
Lysozyme activity assay
The lysozyme activity was assayed based on the method
of Thammasirirak et al. [35], using lyophilized cells of
all stains used previously as a substrate. Cell suspension
in 0.1 M sodium phosphate buffer, pH 7.0, was diluted
a n da d j u s t e dt oO D 540 of 0.7-0.8 at 540 nm. Enzyme
solution (100 μL) was added to 3 mL of cell suspension.
The enzymatic activity was evaluated from the decrease
of absorbance at 540 nm for 3 min. One enzyme unit
was defined as the amount of lysozyme causing a
decrease of 0.1 absorbance units in the reaction mixture
for 1 min at 25°C. The assay was performed in triplicate
per sample.
Effect of lysozyme pretreatment on the ability of ChPLA2-IIA
to hydrolyse cell suspensions
Cell suspensions (10
7 cells/ml) of several bacteria, were
incubated with 2.5 mg/ml of lysozyme for 2 min prior
to the addition of 45 μg/ml of the ChPLA2-IB and
ChPLA2-IIA. Samples were incubated for 20, 60 and
120 min and then plated for 24 h to measure colony-
forming units (CFU).
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